As high GILT mRNA expression was associated with improved survival in metastatic melanoma patients treated with ICI and as GILT has a well-established role in antigen presentation and enhancing T cell responses [23,24,25,43], the association of GILT protein expression in metastatic melanoma cells with clinical outcome in patients treated with ICI was tested. This evidence concerns the gene IFI30 and metastatic melanoma.